drugset / Trial / NCT02386800

CINC424A2X01B Rollover Protocol

NCT02386800

Phase 4 Active not recruiting 279 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This is a long term safety study for patients that have been treated with either ruxolitinib or a combination of ruxolitinib with panobinostat, on a Novartis or Incyte sponsored study, who have been judged by the study Investigator to benefit from ongoing treatment.

Timeline

Start
2015-03-05
Primary completion
2027-09-16
Completion
2032-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Panobinostat Small molecule Oral
Subject Ruxolitinib Small molecule Oral